Investegate |Immunicum AB Announcements | Immunicum AB: Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting

Immunicum AB
Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting
Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting
Press Release
03 May 2021
Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting
Immunicum AB (publ; IMMU.ST) announced today the publication of two abstracts for oral presentations covering preclinical data on its lead programs, ilixadencel and DCP-001, at the 18
th
Cancer Immunotherapy (CIMT) Annual Meeting, held virtually from Monday, May 10 to Wednesday, May 12, 2021. The accepted abstracts are now available on the conference website. The presentations cover updated preclinical data on the combination of ilixadencel with a checkpoint inhibitor targeting CTLA4 and new preclinical data on the mechanism of action of DCP-001 and its combination with the emerging immunotherapy target CD47.

Related Keywords

Sweden ,Netherlands ,Stockholm ,Sijme Zeilemaker ,Erik Manting ,Eva Mulder ,Sophia Hergenhan ,Satwinder Kaur Singh ,Alex Karlsson Parra ,Research At Immunicum ,Trophic Communications ,Preclinical Data ,Annual Meeting ,Chief Scientific Officer ,Talk Session ,Investor Relations ,Investegate Announcements ,Investegate Company Announcements ,Immunicum Ab ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,ஸ்வீடந் ,நெதர்லாந்து ,ஸ்டாக்‌ஹோல்ம் ,ஈவா முல்டர் ,ஆண்டு சந்தித்தல் ,தலைமை அறிவியல் அதிகாரி ,பேச்சு அமர்வு ,முதலீட்டாளர் உறவுகள் ,ந்வ் ,